TDA, I like the analysis. To my mind the only question is around the ability to capture 40% SOM at a discount of only 10% to the branded product. You also have to look at the longevity of being the sole generic in the mix to determine a multiple so I would err on the lower end.
That being said there is currently no value being ascribed to HyCamp or any or its other versions.
I have been long the stock over many years now and continue to hold. I was even lucky enough to purchase some at around the 11 cents range (not enough!)
Here's hoping for a positive FDA verdict and a significant rerating.
(This is not intended as financial advice, always seek independent qualified financial advice before making any investment decisions)
- Forums
- ASX - By Stock
- TSN
- arixtra sales
arixtra sales, page-2
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LGP
Record revenue of $10.2 million as European demand drives 40% quarterly growth, with $1 million in operating cash inflow and $0.5 million in cost savings forecast
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable